Skip to content

Efficacy of Autologous Adipose Derived Stromal Vascular Fraction for Musculoskeletal Conditions

Efficacy of Autologous Adipose Derived Stromal Vascular Fraction for Musculoskeletal Conditions

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06000670
Acronym
SVF
Enrollment
300
Registered
2023-08-21
Start date
2026-12-30
Completion date
2028-12-01
Last updated
2025-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Keywords

knee osteoarthritis, knee chondromalacia

Brief summary

clinical efficacy of autologous stromal vascular fraction SVF,for inflammatory and degenerative conditions of the knees

Detailed description

to evaluate the clinical effectiveness of point of care autologous adipose derived stromal vascular fraction (SVF) alone or in combination with exosomes,for inflammatory and degenerative conditions of the knees.

Interventions

PROCEDUREstromal vascular fraction injection in the osteoarthritic knee

stromal vascular fraction harvested from mid abdominal wall under sedation and seperated from fat using mechanical centrifugation .injection of 5 cc of the SVF in the affected knee.

Sponsors

Dubai Health Authority
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Masking description

investigator is blinded to clinical and radiological assessments .

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* knee osteoarthritis any grade * knee chondromalacia grade 2 and above

Exclusion criteria

* active HIV * pregnant women * Mental disease * severe cardio vascular disease * severe coagulation disorders * infected tissues * patients on other experimental studies within 3 months

Design outcomes

Primary

MeasureTime frameDescription
change in pain level2 yearsvisual analog scale 0-10 ( 10 being worst)

Secondary

MeasureTime frameDescription
percentage cartilage thickness change2 yearsas measured by MRI

Contacts

Primary ContactAmer Mansour, MD
dramermansour@gmail.com+971502983375
Backup Contactmazen sawaf, MD
drmax@novomed.com+971504545266

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026